Article

Salivary Microbial Signature Highlighting Actinomyces as a Predictor of Immune-Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer.

2025-11-10

Abstract excerpt

<title>Abstract</title> <p> Background Immune checkpoint inhibitors (ICIs) have improved survival in advanced non-small cell lung cancer (NSCLC), yet reliable biomarkers beyond programmed death-ligand 1 (PD-L1) expression remain limited. Increasing evidence links the gut microbiome to ICI activity, but the predictive value of the oral microbiome is poorly defined. Methods We prospectively analyzed baseline saliv...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 50f3c2e7-a2b5-53f3-8195-12289ecec7f1
DOI: 10.21203/rs.3.rs-7885686/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Salivary Microbial Signature Highlighting Actinomyces as a Predictor of Immune-Checkpoint Inhibitor Response in Advanced Non–Small Cell Lung Cancer.DOI 10.21203/rs.3.rs-7885686/v1Read

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefitSemantic proximity Read

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancerSemantic proximity Read

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read

Gut Microbiome Diversity and Specific Composition During Immunotherapy in Japanese Responders with Non-Small Cell Lung CancerSemantic proximity Read

Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancerSemantic proximity Read

Microbial Determinants of Immune Activation and Clinical Outcome in Lung Tumor SubtypesSemantic proximity Read

Gut Metatranscriptomics Based De Novo Assembly Reveals Microbial Signatures Predicting Immunotherapy outcomes in Non-Small Cell Lung CancerSemantic proximity Read

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut MicrobiotaSemantic proximity Read

Relationship of The Lung Microbiome With PD-L1 Expression And Immunotherapy Response in Lung CancerSemantic proximity Read

Microbial Biomarkers for Lung Cancer: Current Understandings and LimitationsSemantic proximity Read

The Airway Microbiota of Non-Small-Cell Lung Cancer Patients and Its Relationship to Tumor Stage and EGFR MutationSemantic proximity Read

Intratumoral Microbiota Impacts the First-Line Treatment Efficacy and Survival in Non-Small Cell Lung Cancer Patients Free of Lung Infection.Semantic proximity Read